Tennessee Senate Holds Hearing on Bill Regarding Abortion Drug’s Risks

State   |   Steven Ertelt   |   Apr 10, 2007   |   9:00AM   |   WASHINGTON, DC

Tennessee Senate Holds Hearing on Bill Regarding Abortion Drug’s Risks Email this article
Printer friendly page

by Steven Ertelt
LifeNews.com Editor
April 10
, 2007

Washington, DC (LifeNews.com) — A state Senate committee held a hearing on a measure that would require abortion practitioners to tell women about the risks and dangers associated with the abortion drug RU 486. The Senate Judiciary Committee heard debate on the bill but postponed a vote on it until a later date.

Under the measure, the abortion practitioner would inform women of the risks associated with the abortion drug, also known as Mifeprex, before giving it to her.

According to FDA reports, there have now been eight known deaths associated with RU 486 in the United States alone and thirteen women have died worldwide after using the drug.

FDA records also show, as of December, that there were nine life-threatening incidents, 116 blood transfusions, and 232 hospitalizations in the United States since the drug was approved for use in the waning days of the Clinton administration.

In total, more than 1,050 women have had medical problems after using the drug.

The bill in question would also require abortion practitioners to do an ultrasound on women using the abortion drug to verify the stage of pregnancy since the RU 486 abortion drug could cause severe problems if not restricted to the early stages of pregnancy.

Senator Jack Johnson, a Republican, is the sponsor of the bill and said it would protect the health and safety of women. He pointed out that one of the American women who died from using the abortion drug lived in Chattanooga.

"We have a serious drug, a drug that’s killing women in some circumstances when it’s not used properly," he said.

However, Senator Beverly Marrero, a Memphis Democrat, opposed the safety bill and said it was an attempt to limit abortions.

One leading doctor familiar with the abortion drug said last year that more should be done in response to the abortion drug injuring women.

Dr. James McGregor, an obstetrics professor at the University of Colorado Health Sciences Center, told an FDA panel hat the problems are sufficient to warrant limiting the use of the abortion drug or pulling it from the market entirely.

"I recommend we reduce or eliminate mifepristone, or at least consider that," McGregor said.

Related web sites:
Tennessee legislature – https://www.legislature.state.tn.us